Ultragenyx Pharmaceutical RARE announced that it has reached alignment with the FDA regarding the phase III study design and endpoints for GTX-102, an antisense oligonucleotide for Angelman syndrome, following the completion of a successful end-of-phase II meeting with the regulatory body. The company expects to initiate the same by the end of 2024. In the meeting, Ultragenyx mainly discussed the positive interim data from the phase I/II study, announced in April 2024, with the FDA. The study evaluated the safety and tolerability of GTX-102 administered by intrathecal injection to pediatric patients with Angelman syndrome, a rare and neurogenetic disorder, with a genetically confirmed diagnosis of full maternal UBE3A gene deletion. Per RARE, the pivotal phase III sham-controlled study will evaluate the safety and primary efficacy of GTX-102 in approximately 120 Angelman syndrome patients, with a genetically confirmed diagnosis of full maternal UBE3A gene deletion over a 48-week treatment period. The primary endpoint of the late-stage study will be the improvement in cognition assessed by the Bayley-4 cognitive raw score. Patients in the control group who complete the study can switch to treatment once the double-blind phase concludes. Year to date, shares of Ultragenyx have lost 8.2% compared with the industry’s 1% decline. Zacks Investment Research Image Source: Zacks Investment Research The company also reported that the phase III study will assess the Multi-domain Responder Index across cognition, receptive communication, behavior, gross motor function and sleep as a key secondary endpoint. Individual secondary endpoints for communication, behavior, motor function and sleep have been agreed upon with the FDA as well. Further feedback on the conduct and analysis of these endpoints may be provided by the FDA's Division of Clinical Outcomes Assessment. In the EU, Ultragenyx has met with the European Medicines Agency in a PRIME meeting, receiving approval for the phase III study design, dosing and evaluations. It also plans to meet with the Japanese regulatory body in the coming weeks to discuss the same. Alongside the planned pivotal phase III study, RARE also discussed with the FDA its plans to initiate an open-label clinical study to evaluate the safety and efficacy of GTX-102 for treating other Angelman syndrome genotypes in other patient age groups. This additional study aims to enable treatment for a broader range of Angelman syndrome patients. At present, there are no approved disease-modifying treatments for Angelman syndrome, which represents a significant unmet medical need for patients suffering from the disease. Ultragenyx Pharmaceutical Inc. Price and Consensus Ultragenyx Pharmaceutical Inc. Price and Consensus Ultragenyx Pharmaceutical Inc. price-consensus-chart | Ultragenyx Pharmaceutical Inc. Quote Zacks Rank & Stocks to Consider Ultragenyx currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. ANIP, Adaptive Biotechnologies Corporation ADPT and RAPT Therapeutics, Inc. RAPT, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for ANI Pharmaceuticals 2024 earnings per share (EPS) have improved from $4.41 to $4.44. EPS estimates for 2025 have improved from $4.85 to $5.42. Year to date, shares of ANIP have jumped 14.2%. ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 53.90%. In the past 60 days, estimates for Adaptive Biotechnologies’ 2024 loss per share have narrowed from $1.30 to $1.29, while loss per share estimates for 2025 have narrowed from $1.08 to $1.02. Year to date, shares of ADPT have lost 11.2%. ADPT’s earnings beat estimates in two of the trailing four quarters, meeting the same once and missing on the remaining occasion, the average surprise being 0.65%. In the past 60 days, estimates for RAPT Therapeutics’ 2024 loss per share have narrowed from $2.94 to $2.93. Loss per share estimates for 2025 have narrowed from $2.06 to $2.05. Year to date, shares of RAPT have plunged 85.4%. RAPT’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 3.19%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ANI Pharmaceuticals, Inc. (ANIP):Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE):Free Stock Analysis Report Adaptive Biotechnologies Corporation (ADPT):Free Stock Analysis Report Rapt Therapeutics (RAPT):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...